Navigation Links
Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device
Date:3/8/2011

major and minor adverse events associated with VCD and closure.  

As pre-specified, enrollment was terminated following analysis of the first 64 patients enrolled because of the statistically significant difference in comfort detected.   The reduction in pain favoring the Mynx device compared to the Angio-Seal Evolution device was highly significant for both primary and secondary endpoints, which measured the pain at closure and the change in pain from baseline (pre-closure) to closure.  Over twice as many patients undergoing closure by Angio-Seal closure as those undergoing Mynx closure reported the most painful part of the procedure to be VCD deployment (88% vs. 34%, p<0.001).  The large difference in pain experienced between Mynx and Angio-Seal patients was hypothesized to be secondary to the presence or absence of compression elements within the devices.  No major or minor adverse events were reported in patients undergoing either Mynx or Angio-Seal closure procedures, although the study was not powered to detect a difference in adverse complications.

"Patient comfort is an important aspect in selecting a vascular closure device and every step taken to improve the patient's experience is a step in the right direction," said Dr. J. Mocco, (Department of Neurosurgery, University of Florida College of Medicine, Gainesville, FL), co-author of the study.

The Mynx device is indicated for use to seal femoral arterial access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.  The Mynx device has not been approved for the reduction of pain in VCD procedures.

About AccessClosure

Founded in 2002, AccessClosure, Inc. is a privately held medical device company pioneering innovative access site management products designed to provide a reliable, patient-friendl
'/>"/>

SOURCE AccessClosure, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Georgia Health Sciences University Clinical Study Shows RyMed InVision-PlusĀ® IV Connector Significantly Decreased Central Venous Catheter Occlusions in Oncology Patients
2. Leading Animal Stem Cell Developer MediVet-America Achieves Significant Business Growth Milestones in First Year
3. The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI)
4. Structured Diabetes Management can Significantly Improve Overall Glycemic Control and Reduce HbA1c Values in Non-insulin Treated Type 2 Diabetes
5. Integrated Analysis Demonstrates Alpha(1)-Augmentation Therapy Significantly Reduces Loss of Lung Tissue in Patients with AAT-deficiency-related Emphysema
6. US Dominance in Scientific Research Significantly Challenged by Increased Competition from Europe and Asia, According to Thomson Reuters Study
7. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
8. STALLERGENES : Significant Growth : Q3 2010 + 10% and +12% Over the First 9 Months / Shionogi Partnership: First EUR24 Million Instalment
9. Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
10. Cord Blood America Says Outreach Program to OB/GYN Nurses, Insurance Case Workers, Paying Significant Dividends
11. Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Pipette.com has added ... to their comprehensive portfolio of Eppendorf products. , The ... purchase a Centrifuge 5424/5424 R and receive the following:, ... Eppendorf Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... 2015 Diagenode, Inc., a leading ... Bioruptor® and complete solutions for epigenetics research, recently ... alleviating the need for manual processing. The new ... ChIP of histones or transcription factors and a ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: BLFS ), ... hypothermic storage and cryopreservation freeze media ... tissues  ("BioLife" or the "Company"), today announced that it will ... 2015 (the "Annual Meeting"). Because the expected date ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... ... ... - Interaction of nimotuzumab with EGFRvIII, a mutant form of EGF receptor frequently ... , , ...
... LONDON and ... Matrix,Corporate Capital ("Matrix") and PharmaVentures Limited ("PharmaVentures"),today ... ("MOU") covering,strategic transactions in the biotech, pharmaceutical and ... identify licensing, buyout, investment,IPO and consolidation opportunities which ...
... Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients ... ... , ... ...
Cached Biology Technology:YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 2YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 3YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 4YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 5YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 6YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 7Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU) 2Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU) 3Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU) 4NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 2NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 3NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 4NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 5NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 6NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 7NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 8NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 9NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 10NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 11NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 12NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 13
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform ... State of Washington,s Department of Licensing, in the ... issuance system for driver,s licenses and identification cards to its ... development will start in January 2015, with enrollment and card ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a ... discovery, announced the launch of a TR-FRET (time ... company,s Transcreener UDP Assay, a high throughput screening ... new assay will allow for sensitive detection of ...
(Date:1/22/2015)... 21, 2015  Analyst Report Issued by Small Cap IR. In ... that planet-wide, transactions at merchants on the leading payment cards ... of credit, debit, and prepaid cards reached 6.54 billion.  Eight ... fraudulent card usage in 2012, and credit and debit card ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... LAFAYETTE, Ind. - Warmer, drier summers and extreme weather ... especially troublesome - possibly fatal - for walnut trees, ... years, Douglass Jacobs, a professor of forestry and natural ... Jacobs who is now a research scientist in the ...
... effects of climate warming on biodiversity pose a serious conservation ... Science .,Marine life may need to relocate faster than ... timing of major life cycle events. This challenges previous thinking ... than species on land because of slower warming in the ...
... of Cambridge study, which set out to investigate DNA methylation ... lifestyle and our health, has now mapped the link in ... collected greatly benefits a field that is still in its ... the researchers were, even 18 months ago. Researcher ...
Cached Biology News:Walnut trees may not be able to withstand climate change 2No plain sailing for marine life as climate warms 2No plain sailing for marine life as climate warms 3Environment and diet leave their prints on the heart 2
... Compliant software for JASCO HPLC systems. , Integrated Instrument Control ... EZChrom Elite ... for JASCO HPLC systems. This provides a completely integrated system to ... with each run. , ...
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
... SilverSNAP Stain for Mass Spectrometry Applications ... spectrometry (MS) has emerged as a powerful ... of 2-D gels is now an important ... that leads ultimately to identification of specific ...
... Protein Extraction Reagent is a ... that means no scraping, no ... With M-PER Reagent, rapid lysis ... at room temperature, yielding 25% ...
Biology Products: